PSMA Lentivirus

Catalog #
78726
$995 *
Size: 500 µl x 2
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The PSMA Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. The particles contain a human PSMA (NM_ 004476.3) driven by a CMV promoter and a puromycin selection marker (Figure 1).

Figure 1: Schematic of the lenti-vector used to generate the PSMA Lentivirus.

Synonyms
Glutamate carboxypeptidase 2, FOLH1, FOLH, NAALAD1, PSM, GIG27, GIG27, FGCP, GCPII, mGCP, NAALADase I, PSM, Cell growth-inhibiting gene 27 protein, Folate hydrolase 1, Folylpoly-gamma-glutamate carboxypeptidase, Glutamate carboxypeptidase II
Product Info
Storage and Usage
Citations
Supplied As
Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Formulation

The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS.

UniProt #
Q04609
Background

PSMA (prostate-specific membrane antigen, also known as Folate hydrolase 1, FOLH1), is highly expressed in prostate cancer cells and is used as a diagnostic and prognostic indicator of prostate cancer. The enzyme has folate hydrolase and peptidase activity. It plays a role in prostate cancer progression through the PI3K-Akt and MAPK-ERK1/2 pathways. PSMA/FOLH1is used in the clinic as a target for PET (positron emission tomography) imaging of prostate cancer whereas radioactive analogs are used for the treatment of prostate cancer. It is also expressed in other tumor types and in a few normal tissues. PSMA/FOLH1 is the target of CAR-T cells and bi-specific antibodies currently under development.